Back to results
US 5,965,790 AGranted
SR-BI regulatory sequences and therapeutic methods of use
AssigneeMillennium Pharmaceuticals, Inc.
InventorSusan Laurene Acton
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeMillennium Pharmaceuticals, Inc.
InventorSusan Laurene Acton
Estimating the term…
The invention features nucleic acid molecules that are involved with (e.g. activate or regulate) human SR-BI receptor transcription, as well as complements thereto, and homologs thereof. In addition, drug discovery assays are provided for identifying agents which modulate SR-BI promoter activity and thereby modulate the expression of a gene regulated thereby. Such agents can be useful therapeutically for treating or preventing the development of a disease or condition that is caused or contributed to by an aberrant SR-BI activity. In a preferred embodiment, the disease or condition is characterized by inappropriate lipid transfer or metabolism (e.g., atherosclerosis or gallstone formation). Such agents can also be used to modulate expression of a specific gene under the control of the SR-BI promoter in gene therapy. Moreover, the present invention provides diagnostic assays and reagents for determining whether a subject has a disorder involving, for example, aberrant expression of SR-BI genes.
An isolated nucleic acid molecule which is capable of hybridizing to a nucleic acid molecule consisting of the nucleotide sequence from nucleotide 610 to nucleotide 1595 of SEQ ID NO:
A method for identifying a test compound that modulates transcription from an SR-BI promoter, comprising the steps of:
A method for identifying a test compound that modulates transcription from an SR-BI promoter comprising the steps of:
An isolated nucleic acid molecule contained in ATCC Deposit No 98304.
An isolated nucleic acid comprising a nucleotide sequence set forth in any of SEQ ID NO:
An isolated nucleic acid comprising the nucleotide sequence from about nucleotide 610 to about nucleotide 1595 of SEQ ID NO:
An isolated nucleic acid comprising the nucleotide sequence from about nucleotide 900 to about nucleotide 1595 of SEQ ID NO:
Dependencies are inferred from the claim text.